Literature DB >> 19064871

Tolerability, adherence, and patient outcomes.

Amy Perrin Ross1.   

Abstract

Providing optimal patient care in multiple sclerosis (MS) is dependent on both the patient and the healthcare system. One of the greatest challenges to optimal patient care is ensuring patient adherence to treatment. The two reasons given most often for treatment discontinuation are adverse effects and lack of efficacy. Adverse effects can be anticipated and managed, in part through well-established protocols, but also through industry-sponsored nursing support programs. These strategies can reduce needless discontinuations when patients experience common adverse effects. Lack of efficacy can be addressed for many patients by providing them with enough education to develop reasonable expectations for treatment and long-term prognosis. As important as early and continuous treatment are, these strategies are essential for providing optimal patient care in MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19064871     DOI: 10.1212/WNL.0b013e31818f3dcb

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.

Authors:  Pasquale De Fazio; Paolo Girardi; Giuseppe Maina; Massimo Carlo Mauri; Mauro Mauri; Palmiero Monteleone; Giulia Ida Perini; Giulio Perugi; Alessandro Rossi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics.

Authors:  Jeffrey R Curtis; Coburn Hobar; Kevin Hansbrough
Journal:  Curr Med Res Opin       Date:  2010-11-22       Impact factor: 2.580

3.  Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Authors:  Peter J Jongen; Gerald Hengstman; Raymond Hupperts; Hans Schrijver; Job Gilhuis; Joseph H Vliegen; Erwin Hoogervorst; Marc van Huizen; Eric van Munster; Johnny Samijn; Els de Schryver; Theodora Siepman; Martijn Tonk; Eveline Zandbergen; Jacques ten Holter; Ruud van der Kruijk; George Borm
Journal:  BMC Neurol       Date:  2011-03-30       Impact factor: 2.474

4.  When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?

Authors:  Mona Alkhawajah; Joel Oger
Journal:  Mult Scler Int       Date:  2011-05-17

5.  Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.

Authors:  Claire Meyniel; Timothy Spelman; Vilija G Jokubaitis; Maria Trojano; Guillermo Izquierdo; François Grand'Maison; Celia Oreja-Guevara; Cavit Boz; Alessandra Lugaresi; Marc Girard; Pierre Grammond; Gerardo Iuliano; Marcela Fiol; Jose Antonio Cabrera-Gomez; Ricardo Fernandez-Bolanos; Giorgio Giuliani; Jeannette Lechner-Scott; Edgardo Cristiano; Joseph Herbert; Tatjana Petkovska-Boskova; Roberto Bergamaschi; Vincent van Pesch; Fraser Moore; Norbert Vella; Mark Slee; Vetere Santiago; Michael Barnett; Eva Havrdova; Carolyn Young; Carmen-Adella Sirbu; Mary Tanner; Michelle Rutherford; Helmut Butzkueven
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 6.  Role of lipoic acid in multiple sclerosis.

Authors:  Hongsheng Xie; Xiufang Yang; Yuan Cao; Xipeng Long; Huifang Shang; Zhiyun Jia
Journal:  CNS Neurosci Ther       Date:  2021-12-28       Impact factor: 5.243

7.  Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Authors:  Uwe Klaus Zettl; Ulrike Bauer-Steinhusen; Thomas Glaser; Klaus Hechenbichler; Michael Hecker
Journal:  BMC Neurol       Date:  2016-09-21       Impact factor: 2.474

8.  Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.

Authors:  Barry Hendin; Robert T Naismith; Sibyl E Wray; Deren Huang; Qunming Dong; Terrie Livingston; Daniel L Jones; Crystal Watson; Mehul Jhaveri
Journal:  Patient Prefer Adherence       Date:  2018-07-20       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.